Exact peptide identities attached to retained registry observations carrying this condition label.
Official registry condition
Diabetes peptide trials
13 selected ClinicalTrials.gov records carrying the official condition label Diabetes. The label is copied from each retained registry version and does not imply that PeptideScanner has verified a diagnosis, treatment relationship, or study result.
13 selected records.
6 profiles.
2014–2026 in selected records.
Indication intelligence
Selected evidence landscape
Phase labels copied from the retained ClinicalTrials.gov versions.
Overall statuses at each retained observation, not necessarily current today.
Across the connected peptide profiles, PeptideScanner also carries 256 selected PubMed records and 27 selected Drugs@FDA applications. Those records are profile context only; PeptideScanner does not claim they concern Diabetes unless their own cited source says so.
Collection change ledger
Recently changed records on this condition hub
These events come only from the exact registry records shown on this page. The condition label does not establish a diagnosis, treatment relationship, or scientific agreement.
ClinicalTrials.gov record NCT00657605
PeptideScanner retained ClinicalTrials.gov record NCT00657605 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-02-13, and PeptideScanner's reviewed identity mapping was metreleptin.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- February 13, 2020
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT00659828
PeptideScanner retained ClinicalTrials.gov record NCT00659828 at 2026-11-16T17:35:38.955Z. Its registry update date was 2020-02-13, and PeptideScanner's reviewed identity mapping was metreleptin.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- February 13, 2020
- Evidence lane
- Clinical trials
ClinicalTrials.gov record NCT01977859
PeptideScanner retained ClinicalTrials.gov record NCT01977859 at 2026-11-16T01:39:41.882Z. Its registry update date was 2018-02-14, and PeptideScanner's reviewed identity mapping was nesiritide.
- PeptideScanner change date
- November 16, 2026
- Cited source date
- February 14, 2018
- Evidence lane
- Clinical trials
Attributed registry records
Selected records
Metreleptin · 2026-11-09
ClinicalTrials.gov record NCT02262806
Active, not recruiting at the retained observation.
Open attributed record →Metreleptin · 2026-10-27
ClinicalTrials.gov record NCT02262832
Active, not recruiting at the retained observation.
Open attributed record →Dalbavancin · 2022-09-21
ClinicalTrials.gov record NCT04959799
Completed at the retained observation.
Open attributed record →Secretin · 2020-11-05
ClinicalTrials.gov record NCT04613700
Completed at the retained observation.
Open attributed record →Metreleptin · 2020-02-13
ClinicalTrials.gov record NCT00657605
Completed at the retained observation.
Open attributed record →Metreleptin · 2020-02-13
ClinicalTrials.gov record NCT00659828
Completed at the retained observation.
Open attributed record →Semaglutide · 2019-06-19
ClinicalTrials.gov record NCT03466567
Completed at the retained observation.
Open attributed record →Semaglutide · 2018-06-13
ClinicalTrials.gov record NCT02064348
Completed at the retained observation.
Open attributed record →Semaglutide · 2018-04-18
ClinicalTrials.gov record NCT02146079
Completed at the retained observation.
Open attributed record →Nesiritide · 2018-02-14
ClinicalTrials.gov record NCT01977859
Completed at the retained observation.
Open attributed record →Semaglutide · 2017-12-02
ClinicalTrials.gov record NCT02079870
Completed at the retained observation.
Open attributed record →Semaglutide · 2017-04-04
ClinicalTrials.gov record NCT02022254
Completed at the retained observation.
Open attributed record →Liraglutide · 2014-12-09
ClinicalTrials.gov record NCT01507389
Completed at the retained observation.
Open attributed record →